Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease
-
Altmetric Citations
Subramaniam, Kavitha; Fallon, Kieran; Ruut, Tom; Lane, D; McKay, R.; Shadbolt, Bruce; Ang, S.; Cook, Matthew; Platten, J.; Pavli, Paul; Taupin, Douglas
Description
Background Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF-κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim As TNF is a potent activator of NF-κB, and anti-TNF agent infliximab (IFX) prevents NF-κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods We performed a...[Show more]
Collections | ANU Research Publications |
---|---|
Date published: | 2015 |
Type: | Journal article |
URI: | http://hdl.handle.net/1885/164703 |
Source: | Alimentary pharmacology & therapeutics |
DOI: | 10.1111/apt.13058 |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Subramaniam_Infliximab_reverses_2015.pdf | 482.77 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator